High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Manasa, Justen ^a   Lessells, Richard J ^a,b   Skingsley, Andrew ^a   Naidu, Kevindra K ^a   Newell, Marie Louise ^a,c   McGrath, Nuala ^a,d   de Oliveira, Tulio ^a,e  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENETIC ALGORITHM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIMARY HEALTH CARE; RURAL AREA; SEQUENCE ANALYSIS; SOUTH AFRICA; SUBSTITUTION THERAPY; TREATMENT DURATION; UNINDEXED SEQUENCE; VIRUS LOAD;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; BENZOXAZINES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; NEVIRAPINE; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; SOUTH AFRICA; STAVUDINE; YOUNG ADULT; ZIDOVUDINE;

EID: 84882687089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072152     Document Type: Article

References (60)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2011) World AIDS Day Report 2011. Geneva, Switzerland: UNAIDS.
2. Herbst AJ, Cooke GS, Barnighausen T, KanyKany A, Tanser F, et al. (2009) Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ 87: 754-762.
3. Bor J, Herbst AJ, Newell ML, Barnighausen T, (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961-965.
4. Hamers RL, Kityo C, Lange JM, Wit TF, Mugyenyi P, (2012) Global threat from drug resistant HIV in sub-Saharan Africa. BMJ 344: e4159.
5. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, et al. (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368: 505-510.
6. Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, et al. (2011) Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. Aids 25: 1761-1769.
7. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, et al. (2011) Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 343: d6792.
8. Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, et al. (2012) Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients. Antivir Ther 17: 377-386.
9. Levison JH, Orrell C, Losina E, Lu Z, Freedberg KA, et al. (2011) Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa. Antivir Ther 16: 853-861.
10. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, et al. (2011) Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa. J Acquir Immune Defic Syndr 58: 23-31.
11. Johnston V, Fielding K, Charalambous S, Mampho M, Churchyard G, et al. (2012) Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS One 7: e36997.
12. Singh A, Sunpath H, Green TN, Padayachi N, Hiramen K, et al. (2011) Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options. J Acquir Immune Defic Syndr 58: 233-240.
13. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, et al. (2008) Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. Aids 22: 2210-2212.
14. El-Khatib Z, DeLong AK, Katzenstein D, Ekstrom AM, Ledwaba J, et al. (2011) Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa. J AIDS Clinc Res 2: 117.
15. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 24: 1679-1687.
16. Hoffmann CJ, Charalambous S, Sim J, Ledwaba J, Schwikkard G, et al. (2009) Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 49: 1928-1935.
17. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, et al. (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 46: 1589-1597.
18. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, et al. (2009) HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 14: 523-531.
19. Pillay V, Pillay C, Kantor R, Venter F, Levin L, et al. (2008) HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 24: 1449-1454.
20. Sigaloff KC, Ramatsebe T, Viana R, Wit TF, Wallis CL, et al. (2011) Accumulation of HIV Drug Resistance Mutations in Patients Failing First-Line Antiretroviral Treatment in South Africa. AIDS Res Hum Retroviruses.
21. van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W, (2011) Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the western cape, South Africa. J Med Virol 83: 1764-1769.
22. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W, (2010) Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 53: 480-484.
23. Wallis CL, Papathanasopolous MA, Fox M, Conradie F, Ive P, et al. (2012) Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther 17: 313-320.
24. Census 2011 Metadata. Pretoria: Statistic South Afria, 2012.
25. Versteeg M, Couper I (2011) Rural Health- Key to a Healthy Nation. Johannesburg: Rural Health Advocacy Project.
26. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, et al. (2010) Cohort Profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol.
27. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, et al. (2010) Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bull World Health Organ 88: 593-600.
28. Department of Health (2004) National antiretroviral treatment guidelines. Pretoria, South Africa: Department of Health.
29. Department of Health (2010) Clinical guidelines for the management of HIV & AIDS in adults and adolescents. Pretoria, South Africa: Department of Health.
30. de Oliveira T, Shafer RW, Seebregts C, (2010) Public database for HIV drug resistance in southern Africa. Nature 464: 673.
31. Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira For The Southern Africa T, et al. (2012) Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. AIDS Res Hum Retroviruses 28: 558-565.
32. Tshabalala M, Manasa J, Zijenah LS, Rusakaniko S, Kadzirange G, et al. (2011) Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. PLoS ONE 6: e21241.
33. Dalai SC, de Oliveira T, Harkins GW, Kassaye SG, Lint J, et al. (2009) Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. AIDS 23: 2523-2532.
34. Drummond AJ, Ashton B, Buxton S, Cheung M, Cooper A, et al. (2010) Geneious 5.1.
35. Alcantara LC, Cassol S, Libin P, Deforche K, Pybus OG, et al. (2009) A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 37: W634-642.
36. Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, et al. (2009) The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 25: 1197-1198.
37. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.
38. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
39. World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach -2010 revision. Geneva, Switzerland: WHO.
40. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte A, Katlama C, et al. (2009) Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 200: 687-697.
41. Zaccarelli M, Perno CF, Forbici F, Soldani F, Bonfigli S, et al. (2004) Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis 38: 433-437.
42. Miller MD, Margot N, Lu B, Zhong L, Chen SS, et al. (2004) Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189: 837-846.
43. Lessells RJ, Katzenstein DK, de Oliveira T (2012 (in press)) Are subtype differences important in HIV drug resistance? Curr Opin HIV AIDS.
44. Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, et al. (2013) HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrob Agents Chemother 57: 1053-1056.
45. Bangsberg DR, Moss AR, Deeks SG, (2004) Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 53: 696-699.
46. Chaiyachati K, Hirschhorn LR, Tanser F, Newell ML, Barnighausen T, (2011) Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDS 25: 163-170.
47. Cooke GS, Tanser FC, Barnighausen TW, Newell ML, (2010) Population uptake of antiretroviral treatment through primary care in rural South Africa. BMC Public Health 10: 585.
48. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML, (2013) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339: 966-971.
49. Barnighausen T, Tanser F, Newell ML, (2009) Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. AIDS Res Hum Retroviruses 25: 405-409.
50. Johnston V, Fielding KL, Charalambous S, Churchyard G, Phillips A, et al. (2012) Outcomes Following Virological Failure and Predictors of Switching to Second-line Antiretroviral Therapy in a South African Treatment Programme. J Acquir Immune Defic Syndr: 10.1097/QAI.1090b1013e318266ee318263f.
51. Fox MP, van Cutsem G, Giddy J, Maskew M, Keiser O, et al. (2012) Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. J Acquir Immune Defic Syndr.
52. Navario P, (2009) PEPFAR's biggest success is also its largest liability. Lancet 374: 184-185.
53. Department of Health RoSA (2011) National Strategic Plan on HIV, STIs and TB: 2012-2016. Pretoria: South African National AIDS Council.
54. Fatti G, Grimwood A, Mothibi E, Shea J, (2011) The effect of patient load on antiretroviral treatment programmatic outcomes at primary health care facilities in South Africa: a multicohort study. J Acquir Immune Defic Syndr 58: e17-19.
55. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, et al. (2011) Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr 56: e1-8.
56. Barnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, et al. (2011) Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis 11: 942-951.
57. Mepham S, Zondi Z, Mbuyazi A, Mkhwanazi N, Newell ML, (2011) Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa. AIDS Care 23: 741-747.
58. Fried J, Harris B, Eyles J, (2012) Hopes interrupted: accessing and experiences of antiretroviral therapy in South Africa. Sex Transm Infect 88: 147-151.
59. Atun R, Bataringaya J, (2011) Building a durable response to HIV/AIDS: implications for health systems. J Acquir Immune Defic Syndr 57Suppl 2: S91-95.
60. Larson HJ, Bertozzi S, Piot P, (2011) Redesigning the AIDS response for long-term impact. Bull World Health Organ 89: 846-852.